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ABSTRACT 25 
Like many clinical diagnostic laboratories, we undertake routine investigation of 26 
cancer-predisposed individuals by high-throughput sequencing of patient DNA that has 27 
been target-enriched for genes associated with hereditary cancer. Accurate diagnosis 28 
using such reagents requires alertness against rare non-pathogenic variants that may 29 
interfere with variant calling. In a cohort of 2,042 such cases, we identified five that 30 
initially appeared to be carriers of a 95-bp deletion of SMAD4 intron 6. More detailed 31 
analysis indicated that these individuals all carried one copy of a SMAD4 processed 32 
gene. Because of its interference with diagnostic analysis, we characterized this 33 
processed gene in detail. Whole genome sequencing and confirmatory Sanger 34 
sequencing of junction PCR products were used to show that in each of the five cases, 35 
the SMAD4 processed gene was integrated at the same position on chromosome 9, 36 
located within the last intron of the SCAI gene. This rare polymorphic processed gene 37 
therefore reflects the occurrence of a single ancestral retrotransposition event. 38 
Compared to the reference SMAD4 mRNA sequence NM_005359.5 39 
(https://www.ncbi.nlm.nih.gov/nucleotide/), the 5’ and 3’ UTR regions of the processed 40 
gene are both truncated, but its open reading frame is unaltered. Our experience leads 41 
us to advocate the use of an RNA-seq aligner, as part of diagnostic assay quality 42 
assurance, since this allows their recognition in a comparatively facile automated 43 
fashion. 44 
 45 
  46 
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INTRODUCTION 47 
The availability of diagnostic molecular genetic assays has increased significantly in 48 
recent years. This has largely been due to the ubiquitous adoption of next generation 49 
sequencing (NGS) instruments, which have replaced comparatively low-throughput 50 
Sanger sequencing technology, as the standard technique for mutation detection. New 51 
laboratory assays combined with ever-increasing automation is resulting in increased 52 
patient throughput and more efficient workflows. That several genes can be analysed 53 
concurrently has enabled an expansion of testing for heterogeneous genetic disorders 54 
which may have previously been considered too rare for a bona-fide genetic test to have 55 
been established and offered in a routine clinical laboratory. To be able to request a 56 
comprehensive analysis of all genes that correspond to a patient’s phenotype is 57 
transforming diagnostic referral pathways, by eliminating costly ‘test and review’ 58 
processes that are necessary when referrals are made in a consecutive manner. 59 
 60 
Operational requirements associated with test portfolios that can accommodate varying 61 
combinations of target genes have necessitated a fundamental transformation in assay 62 
design. Typically, a far larger range of targets are selected for sequencing than is 63 
suggested a priori from the patient’s presenting phenotype. An in silico virtual gene 64 
panel is applied to these data thus masking inappropriate results from those requested 65 
by the referring clinician. Although this approach generates unnecessary sequence data, 66 
laboratories are able to reduce the complexity of wet-laboratory processes thereby 67 
streamlining their workflows. As the cost of DNA sequencing continues to fall the 68 
number of genes that can be feasibly targeted, while maintaining iteratively comparable 69 
test sensitivity, will continue to increase. Indeed, our originally reported 36-gene 70 
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reagent has been periodically revised and presently targets the coding exons of 155 71 
cancer-associated genes [1]. 72 
 73 
For many commentators, the long-held aspiration that custom-designed panels will be 74 
replaced by exome- and subsequently whole genome-sequencing, is being expedited by 75 
large-scale, population based, sequencing projects. Nevertheless, the prevailing 76 
approach for performing target enrichment, using probe-based hybridisation, has 77 
overcome the need to design and optimise long-range PCR amplicons [2]. This has 78 
improved the scalability of targeted loci, as previously only a finite number of long-79 
range PCR primer pairs could be handled by a single laboratory. Despite this advance, 80 
hybridisation capture methods have a lower specificity for target enrichment due to the 81 
capture of ‘off-target’ sequences. A comparatively greater number of reads it therefore 82 
required to achieve the same depth of coverage (although this is typically off-set by no 83 
longer needing to sequence a gene’s introns). 84 
 85 
Off-target sequences are captured for reasons that may include hybridisation of probes 86 
to low-diversity nucleotide sequences, sequence homology between the targeted region 87 
and that of a related gene family member or an interfering pseudogene, or reaction 88 
kinetics. Although off-target reads are typically ignored, a number of studies have 89 
demonstrated their utility for the inadvertent identification of single nucleotide 90 
polymorphisms [3] and as a source of low-coverage whole genome sequencing reads for 91 
genomewide copy-number analysis [4]. Less useful is the capture and sequencing of 92 
DNA fragments that are highly homologous to target loci; it is usually not possible to 93 
determine the true genomic origin of these resulting data. As pseudogene sequences 94 
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may therefore affect the interpretation of clinical assays their identification and 95 
characterisation is of particular importance to the diagnostic community. 96 
 97 
A SMAD4 processed pseudogene was recently detected in a subset of patients referred 98 
for diagnostic analysis of hereditary cancer predisposition genes [5]. SMAD4 is 99 
associated with both juvenile polyposis syndrome (OMIM: 174900) and combined 100 
juvenile polyposis/hereditary hemorrrhagic telangiectasia syndrome (OMIM: 175050). 101 
Here we corroborate this observation and assess the frequency of the SMAD4 102 
pseudogene in our cohort of 2,042 diagnostically referred hereditary cancer cases. We 103 
further define the genomic integration site and report the transcript structure following 104 
end-to-end sequencing of the identified SMAD4 processed pseudogene. 105 
 106 
 107 
 108 
 109 
 110 
 111 
 112 
 113 
 114 
 115 
 116 
 117 
 118 
 119 
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MATERIALS AND METHODS 120 
Patients were referred to the Leeds Genetics Laboratory for diagnostic testing of one or 121 
more hereditary cancer predisposition genes using a custom-designed SureSelect 122 
hybridisation enrichment assay (Agilent Technologies, Wokingham, UK). The original 123 
36-gene reagent has been iteratively redesigned since the service was launched in 2013 124 
[1] and now targets the exons and immediate flanking sequence of 155 hereditary 125 
cancer genes. 126 
 127 
DNA was isolated from blood lymphocytes using either a standard salting out method or 128 
the ChemagicTM 360 automated extractor (PerkinElmer, Seer Green, UK). For each 129 
sample, an Illumina-compatible sequencing library was generated. Initially, 3 µg of 130 
genomic DNA was sheared using a Covaris S2 or E220 (Covaris Inc., Woburn, MA, USA) 131 
before whole genome library preparation was undertaken using SureSelect XT reagents 132 
(Agilent Technologies, Wokingham, UK). This consisted of end-repair, (A)-addition, 133 
adaptor ligation and PCR enrichment. A custom RNA probeset was used to perform a 134 
targeted capture hybridisation on each of the whole genome libraries, following 135 
manufacturer’s protocols throughout. Samples were initially prepared manually, but a 136 
fully automated solution has since been introduced using a Sciclone G3 liquid handling 137 
workstation (PerkinElmer, Seer Green, UK). The quality and concentration of final 138 
libraries were confirmed using either an Agilent Bioanalyser or Agilent Tapestation 139 
(Agilent Technologies, Wokingham, UK) before, typically, 16 samples were combined 140 
into a single batch for sequencing. Each batch was either sequenced on a single lane of 141 
an Illumina HiSeq2500 rapid-mode flow cell (2 × 101 bp sequencing reads) or pooled 142 
with two additional batches and sequenced on an Illumina NextSeq500 (2 × 151 bp 143 
sequencing reads) using a High Output flow cell using version 2 chemistry (Illumina 144 
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Inc., San Diego, CA, USA). Raw sequence data was converted to FASTQ.gz format using 145 
bcl2fastq v.2.17.1.14. 146 
 147 
A common data processing pipeline, running on the Leeds high-performance computer 148 
MARC1 (http://arc.leeds.ac.uk/systems/marc1/), was applied to each of the per-sample 149 
directories from the SureSelect target enrichment assay. Initially, adaptor sequences 150 
and low-quality bases (Q score ≤10) were trimmed from reads using Cutadapt v.1.9.1 151 
(https://github.com/marcelm/cutadapt) [6]. The resulting analysis-ready reads were 152 
assessed using FastQC v.0.11.5 153 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Reads were next 154 
aligned to an indexed human reference genome (hg19) using BWA MEM v.0.7.13 155 
(https://sourceforge.net/projects/bio-bwa/files/) [7] before being sorted by 156 
chromosome coordinate and having PCR duplicates marked by Picard v.2.1.1 157 
(http://broadinstitute.github.io/picard/) to create a processed.bam file. These data 158 
were realigned using ABRA v.0.97 (https://github.com/mozack/abra) [8] and the 159 
Genome Analysis Toolkit (GATK) v.3.6-0 was used to perform variant calling following 160 
best practice guidelines. This involved indel realignment, base quality score 161 
recalibration and variant calling using the Haplotypecaller to generate a per-sample VCF 162 
file [9]. These variant data were annotated using Alamut Batch Standalone v.1.4.4 163 
(database v.2016.03.04) (Interactive Biosoftware, Rouen, France). Coverage metrics 164 
were determined using the GATK walkers DepthOfCoverage, CallableLoci and 165 
CountReads. Visualisation of aligned sequence reads was performed with the 166 
Integrative Genome Viewer v.2.3.80 (http://software.broadinstitute.org/software/igv/) 167 
[10]. The analysis-ready reads for five samples with apparent SMAD4 intron 6 deletions 168 
were aligned to an indexed hg19 reference genome annotated using GENCODE Release 169 
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26 using the RNA-seq aligner STAR v.2.5.3a with default settings 170 
(https://github.com/alexdobin/STAR/) [11]. 171 
 172 
Illumina-compatible whole genome sequencing libraries were subsequently prepared 173 
for the same five samples. Approximately 3 µg DNA was sheared using a Covaris S2 174 
prior to end-repair, (A)-addition and adaptor ligation steps being undertaken using 175 
NEBNext® UltraTM reagents, following manufacturer’s protocols (New England Biolabs, 176 
Ipswich, MA, USA). An ampure size selection ratio for a 300-bp to 400-bp insert and a 6-177 
cycle enrichment PCR was performed. Following an assessment of library quality, the 178 
final libraries were pooled in equimolar concentrations and the pooled batch was 179 
sequenced using an Illumina NextSeq500 High Output flow cell generating 2 × 151 bp 180 
read lengths. For each sample, a processed.bam file was generated using the same 181 
bioinformatics pipeline described above. Sequence reads mapping to the SMAD4 locus 182 
(chr18:48550000-48620000) were extracted from the coordinate-sorted duplicate-183 
marked bam file using samtools v.0.1.18 with the options -q 1 and -F 14 [12]. These 184 
filters ensured that the mapped read quality score was greater than 0, that neither read 185 
in the pair was unmapped and that the pair was not considered to be a “proper pair”. 186 
Read pairs with one read mapping outside the SMAD4 locus and whose non-SMAD4 read 187 
clustered within 500 bp of the nearest of non-SMAD4 read were reviewed and 188 
compared between patients. 189 
 190 
Three PCR amplicons were generated to amplify across the breakpoints identified by 191 
medium coverage whole genome sequencing. The specificity of the amplicons was 192 
evaluated for each reaction; one primer was located within SCAI intron 18, and the 193 
second primer within the SMAD4 pseudogene. 194 
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 195 
Two amplicons spanning the 5’ end of the SMAD4 pseudogene were designed and 196 
amplified. The first comprised a common SCAI-bound forward primer 5’-197 
CTGAGCTTGTGATCTGCCTG-3’ and the SMAD4 exon 2-located reverse primer 5’-198 
TGAAGCCTCCCATCCAATGT-3’. Each PCR reaction consisted of 7.46 µl nuclease-free 199 
H2O, 1.2 µl, 10× Buffer + Mg, 0.12 µl dNTPs, 2.4 µl GC-rich buffer, 0.12 µl Faststart Taq 200 
polymerase, 0.1 µl 10 µM forward primer, 0.1 µl 10 µM reverse primer and 0.5 µl of 201 
approximately 100 ng/µl DNA (Roche Diagnostics Ltd., Burgess Hill, U.K.). 202 
Thermocycling conditions were 96oC for 5 minutes, followed by 35 cycles of 96oC for 30 203 
seconds, 55oC for 30 seconds, 72oC for 2 minutes and a final 72oC extension step for 10 204 
minutes. The second amplicon was amplified using the same common SCAI-bound 205 
forward primer and a reverse primer specific to SMAD4 exon 8 5’-206 
TGGAAATGGGAGGCTGGAAT-3’. PCR reagents and volumes were equivalent to the first 207 
reaction. Thermocycling conditions were the same, but an additional 5 cycles were 208 
performed. PCR products from the second reaction were gel-extracted and purified 209 
using a QIAquick column following manufacturer’s protocols (Qiagen GmbH, Hilden, 210 
Germany). Sanger sequencing was performed on PCR products from both reactions 211 
using amplification primers and, for the second reaction, a further two internally sited 212 
SMAD4 exon 2 primers (5’-TTCCTTGCAACGTTAGCTGT-3’ and 5’-213 
ACATTGGATGGGAGGCTTCA-3’) with an ABI3730 following manufacturer’s instructions 214 
(Applied Biosystems, Paisley, UK). 215 
 216 
The 3’ end of the SMAD4 processed pseudogene was amplified using a forward primer 217 
bridging the SMAD4 exon 5/6 junction 5’-ACAAGTCAGCCTGCCAGTAT-3’ and an SCAI 218 
reverse primer 5’-CAGGAAACAGCTATGACCTGCAATGACTCGATCTCAGC-3’. The reverse 219 
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primer contained a universal tag (underlined) for Sanger sequencing using our routine 220 
diagnostic workflow. Each reaction consisted of 12.74 µl nuclease-free H2O, 2 µl 221 
SequalPrepTM 10× Reaction Buffer, 0.36 µl SequalPrepTM 5U/µl Long Polymerase, 0.4 µl 222 
dimethyl sulfoxide (DMSO), 2 µl SequalPrepTM 10× Enhancer A, 1 µl 10 µM forward 223 
primer, 1 µl 10 µM reverse primer and 0.5 µl of approximately 100 ng/µl DNA 224 
(Invitrogen, Paisley, UK). Thermocycling conditions comprised a denaturation step of 225 
94oC for 2 minutes, followed by 10 cycles of 94oC for 10 seconds, 60oC for 30 seconds 226 
and 68oC for 3 minutes then 25 cycles of 94oC for 10 seconds 60oC for 30 seconds, 68oC 227 
for 3 minutes with an additional 20 seconds added per cycle, before a final extension 228 
step at 72oC for 5 minutes. PCR products of approximately 2 kb were gel extracted and 229 
purified using the QIAquick column following the manufacturer’s protocol. Sanger 230 
sequencing was performed using the amplification forward primer, universal reverse 231 
primer and the following internally sited primers: 5’-AGCCATTGAGAGAGCAAGGT -3’ 232 
(SMAD4 exon 9/10 forward), 5’-CCTCCAGCTCCTAGACGAAG-3’ (SMAD4 exon 12 233 
forward), 5’-CCATGTGGGTGAGTTAATTTTACC-3’ (SMAD4 exon 12 forward), 5’-234 
TGGAAATGGGAGGCTGGAAT-3’ (SMAD4 exon 8 reverse), 5’-235 
AAAGCAGCGTCACTCTACCT-3’ (SMAD4 exon 12 forward) and 5’-236 
TCAGTTTTTGTATCTTGGGGCA-3’ (SMAD4 exon 12 forward). 237 
 238 
Sequence chromatograms for all Sanger sequencing reactions were analysed using 239 
4Peaks v.1.8 (http://nucleobytes.com/4peaks/index.html). 240 
 241 
RESULTS 242 
Since 2013, we have used a custom-hybridisation enrichment assay and NGS pipeline 243 
for the diagnostic analysis of hereditary cancer genes [1]. In the present study, we 244 
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retrospectively examined 2,042 patient libraries that had been sequenced in 131 245 
batches. We noticed five cases in which our standard variant-calling pipeline identified 246 
an apparent 95-bp deletion, corresponding to the entire SMAD4 intron 6 nucleotide 247 
sequence (c.787+1_788-1del, NM_005359.5, 248 
https://www.ncbi.nlm.nih.gov/nucleotide/). Assay performance metrics for each of 249 
these five libraries are displayed in Supplemental Table S1. 250 
 251 
Visualisation of SMAD4 read coverage charts for the five cases with an apparent intron 6 252 
deletion revealed plots with prominent ‘cliff-edge’ shaped profiles, the discontinuities in 253 
which aligned with the SMAD4 exon-intron boundaries (Supplemental Figure S1). This 254 
was particularly conspicuous for SMAD4 exon 8. Close inspection of these data 255 
established that reads at the exon-intron boundaries had been “soft-clipped”. To further 256 
investigate whether these soft-clipped reads spanned SMAD4 exon-to-exon splice 257 
junctions, sequence reads were mapped to a transcript-annotated human genome, using 258 
the RNA-seq aligner STAR. Resulting Sashimi plots displaying splice junction read 259 
counts were consistent with the presence of a spliced SMAD4 sequence whose exon 260 
structure matched that of the reference mRNA sequence NM_005359.5 261 
(https://www.ncbi.nlm.nih.gov/nucleotide/) (Figure 1). These data thus suggested the 262 
presence of a processed (intron-lacking) SMAD4 pseudogene in these five individuals. 263 
 264 
The existence of such a pseudogene was indeed recently reported [5], although its 265 
structure was not characterized in detail. The frequency (5/2042 = 0.24%) of cases we 266 
observed carrying the SMAD4 pseudogene was in keeping with that reported by Millson 267 
et al. (12/4672 = 0.26%). The likely interference of the pseudogene with diagnostic 268 
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testing prompted us to define its exact structure, and address the question of whether 269 
its sequence and location are identical among carriers. 270 
 271 
To assess the relative number of copies of the SMAD4 pseudogene, we determined the 272 
ratio of gapped (pseudogene-derived) to non-gapped (non-pseudogene) read 273 
alignments spanning intron 6. (Although this region was not specifically targeted when 274 
designing the capture enrichment probes, its small size and proximity to SMAD4 exons 5 275 
and 6 ensured that the intron was fortuitously sequenced.) The ratio of gapped:non-276 
gapped reads was approximately 1:2, suggesting that only a single copy of the 277 
pseudogene was present in each case (Table 1). Further, by comparing the normalised 278 
read-depths of these cases to controls from the same sequencing batches, we 279 
determined relative dosage values for each SMAD4 exon. These results indicated the 280 
presence of three copies of most of the SMAD4 exons, again indicative of a single copy of 281 
the SMAD4 pseudogene (Supplemental Table S2). Although data for exons 4 and 8 282 
deviate from this interpretation, this is probably due to the small genomic intervals 283 
represented by these exons (30 bp and 51 bp, respectively). Additionally, the greater 284 
variability displayed by sample 1 is probably attributable to the reduced number of 285 
available intra-batch controls (9 samples, vs. 15 samples for the other 4 cases). 286 
 287 
Retrospective variant calling was undertaken using VarScan2 [13], to assess the allelic 288 
ratios of coding and non-coding variants. No non-reference coding variants were 289 
identified. However, for sample 4, two variants c.905-52A>G (rs948589) and 290 
c.955+58C>T (rs948588) were present, in introns 7 and 8 respectively. The non-291 
reference read frequencies were 47% for c.905-52A>G (681 of 1455 reads) and 46% for 292 
c.955+58C>T (722 of 1562 reads). This diploid allelic ratio further supports the 293 
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inference that the SMAD4 pseudogene is processed, allelic ratios of intronic SNPs being 294 
unaffected by the presence of the pseudogene. 295 
 296 
To determine whether a common SMAD4 pseudogene integration site was shared 297 
between the five cases, medium-coverage whole genome sequencing (approximately 9× 298 
per sample) was performed. Evidence for the integration site being located on 299 
chromosome 9, within intron 18 of the SCAI gene, was provided by the 16 read pairs 300 
detailed in Table 2. These data characterise DNA fragments whose opposite ends were 301 
each mapped to (a) SCAI intron 18 and (b) either the 5’ (14 read pairs) or 3’ (2 read 302 
pairs) end of SMAD4. Soft-clipped reads spanning the precise integration site indicated 303 
that this was identical, at least among samples 2-5. (For sample 1, no supporting read-304 
pairs were identified, despite there being no obvious difference between the assay 305 
performance metrics, as displayed in Supplemental Table S3.) SMAD4 mapped reads 306 
indicated that the pseudogene sequences for exons 1 and 12 were shorter than those 307 
reported in transcript record NM_005359.5 308 
(https://www.ncbi.nlm.nih.gov/nucleotide/). However, the precise terminal nucleotide 309 
of the 3’-UTR could not be determined from this dataset. This was probably due to the 310 
presence of the poly-A tail, hindering DNA sequencing and mapping, and resulting in an 311 
underrepresentation of exon 12 mapped read pairs. Interestingly, the library insert for 312 
the sample 5 read pair 4:23601:11116:11521 was sufficiently large that the SMAD4-313 
mapped read spanned the exon 1-2 splice junction. 314 
 315 
To confirm the identified integration site, and establish the terminal nucleotide of the 316 
SMAD4 3’-UTR, three overlapping PCR amplicons, each anchored at one end by a primer 317 
bound to SCAI intron 18, were amplified and sequenced (Figure 2). All five cases were 318 
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confirmed to have the same genomic integration site, at which the inserted pseudogene 319 
is flanked by a 4-nt microduplication (TTTC). The exon-exon arrangement was identical 320 
to transcript record NM_005359.5 (https://www.ncbi.nlm.nih.gov/nucleotide/), and no 321 
nucleotide sequence variants were identified in any of the pseudogene exons. Compared 322 
to the mRNA reference sequence, 41 nt are missing from the beginning of the SMAD4 5’-323 
UTR and 5,265 nucleotides are absent from the end of the 3’-UTR. A schematic 324 
representation of the integration site and scale drawing of the gene structure are 325 
displayed in Figure 3. 326 
 327 
DISCUSSION 328 
In recent years, the significantly increased number of genes that are attributable to 329 
clinically recognisable phenotypes have resulted in far greater scope for genetic testing. 330 
Laboratories typically create target enrichment panels that sequence more loci than are 331 
requested by the referring clinician and the unwanted variant data is masked by 332 
creating virtual gene panels in silico. While this approach facilitates the creation of 333 
efficient wet-laboratory processes, it also generates sequence data that is not routinely 334 
analysed. For the purposes of this study we harnessed these data to determine the 335 
frequency of a reported SMAD4 processed pseudogene in our cohort of patients that had 336 
been referred for hereditary cancer testing. We determined the pseudogene to be 337 
present at a frequency of 1 in 408, which is consistent with the previously reported 338 
frequency of 1 in 389 [5]. That the integration site was common to all five patients 339 
suggests that this reflects a single ancestral founder event. Given that the majority of 340 
our laboratory’s referrals are of northern European ancestry it will be interesting to 341 
determine whether this variant is also detected in more diverse ethnic populations. 342 
Unsurprisingly, many other polymorphic processed genes have been found to be 343 
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restricted to certain ethnic groups [14]. Polymorphic processed genes of the present 344 
type have been revealed by large-scale sequencing surveys to be a frequent feature of 345 
the human (and mouse) genome. Although the insertion site of the SMAD4 processed 346 
gene was not determined in the large-scale studies of Ewing et al., (2013) and Shrider et 347 
al., (2013) [14, 15]. 348 
 349 
Most processed genes in the reference human genome are known to be non-functional 350 
(i.e. they are processed pseudogenes), either because they lack promoter sequences 351 
(“dead on arrival”) or have acquired inactivating mutations subsequent to 352 
retrotransposition. However, processed genes whose existence is polymorphic within 353 
the normal population are likely to have been recently transposed, and therefore (as in 354 
the present case) not to have acquired many inactivating mutations. There is 355 
population-level evidence that new processed genes are frequently subject to positive 356 
or negative evolutionary selection [15] as well as anecdotal examples of individual 357 
functional effects of processed genes (discussed in Richardson et al., (2014)) [16].  358 
 359 
Since the coding region of the SMAD4 processed gene is unaltered in comparison to its 360 
parent gene, we cannot be completely certain that it is non-functional (i.e. that it really 361 
is a processed pseudogene). We have been unable to address this question, since RNA is 362 
not available from any of the five carrier individuals, to permit analysis of whether the 363 
processed gene is transcribed. For the same reason, we cannot address any possible 364 
effect of the retrotransposed gene on the splicing of the SCAI gene, within which it is 365 
integrated. A newly transposed processed gene can be disease-causing as a result of 366 
disruption of splicing of its target gene [17]. 367 
 368 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 16
SCAI itself is a nuclear protein that was first characterized for its suppressive effects 369 
upon tumour cell invasiveness, through regulation of beta1-integrin expression [18]. It 370 
has also been shown to be a TP53BP1 interaction partner with an important role in 371 
double-strand break repair [19]. It has been reported that the SCAI 3’-UTR contains a 372 
binding site for miR-1228. When bound, this microRNA is capable of down-regulating 373 
endogenous SCAI protein [20]. Furthermore, SCAI levels have been observed to be 374 
down-regulated in human tumours leading to reports of its tumour suppressor 375 
characteristics. RNA interference experiments of SCAI have shown an upregulation of 376 
β1-integrin gene expression and a resulting increase in invasive cell migration. Despite 377 
these observations, we were unable to obtain relevant tissue specimens from our 378 
patients to determine whether SCAI expression is perturbed by the presence of the 379 
SMAD4 pseudogene. 380 
 381 
Pseudogenes commonly interfere with the diagnostic analysis of clinically important 382 
genes. In extreme cases, unambiguous analysis may be impossible without resort to 383 
highly specialized methodologies; such is the case for mutations in PMS2, which in the 384 
heterozygous or biallelic state cause low-penetrance colorectal cancer predisposition 385 
(Lynch syndrome; OMIM: 614337), and a young-onset mismatch repair cancer 386 
syndrome (OMIM: 276300), respectively [21, 22]. Typically, however, because 387 
pseudogenes are not polymorphic, assay designs can be tailored to avoid interference 388 
and allow robust and reliable clinical diagnosis. 389 
 390 
The ad-hoc discovery of polymorphic processed pseudogenes is likely to become more 391 
frequent as an increasingly genomic approach is applied to molecular diagnostic 392 
investigations. It is perhaps therefore surprising that given the clinical importance of 393 
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SMAD4 [23], no comprehensive analysis of the SMAD4 pseudogene integration site had 394 
hitherto been undertaken. 395 
 396 
While the initial identification of the SMAD4 pseudogene stemmed from aberrant MLPA 397 
result, the clinical adoption of NGS-based hybridisation enrichment panels is outpacing 398 
the production of gene-specific MLPA kits. Consequently, the per-exon cost of 399 
performing MLPA to detect novel pseudogenes, on a large-scale, would likely be cost-400 
prohibitive. Our study demonstrates a convenient approach of using an RNA-seq aligner 401 
to detect processed pseudogenes from hybridisation capture data. We also report how 402 
comparative read depth methods can effectively determine the allelic copy number of 403 
novel pseudogene sequences. Increased demand for genetic testing has meant 404 
laboratories are becoming ever-more reliant on automated variant calling pipelines that 405 
do not involve visualisation of the directly sequenced reads, and clinical scientists are 406 
required to interpret sequence variants for unfamiliar genes. To maintain quality 407 
assurance of these tests, we advocate the inclusion of an RNA-seq aligner into 408 
laboratory pipelines as a means of detecting as-yet unreported polymorphic processed 409 
pseudogenes which, if they remain undetected, could interfere with the interpretation 410 
of clinical results. 411 
 412 
In summary, we report a common genomic integration site for the polymorphic SMAD4 413 
processed pseudogene. We demonstrate how alignment of these data using an RNA-seq 414 
aligner can confirm the presence of splice-junction containing reads. And advocate that 415 
as the number of genes analysed by clinical laboratories continues to expand this would 416 
provide a worthwhile quality assurance approach for target enrichment experiments. 417 
  418 
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FIGURE LEGENDS 542 
Figure 1: SMAD4 Sashimi plots generated following alignment of targeted capture data 543 
using the RNA-seq aligner STAR. Each arc’s corresponding value records the number of 544 
reads crossing the reported splice junction. Alignment coverage data is displayed with 545 
y-axis values ranging from 0-20,000 for Sample 1 and 0-6,000 for all other samples. 546 
 547 
Figure 2: DNA sequence at the common SMAD4 processed gene integration site, located 548 
within SCAI intron 18 (using reference transcript NM_173690.4, 549 
https://www.ncbi.nlm.nih.gov/nucleotide/). Genomic coordinates refer to human 550 
reference genome build hg19. (A) The dashed red line marks the breakpoint 5’ to the 551 
processed gene. (B) The last nucleotide matching the SMAD4 3’ untranslated region is 552 
identified, immediately to the left of the vertical dashed line. To the right of this line is a 553 
poly(A) sequence. (C) The SCAI intron 18 integration site beyond the poly(A) tail. This 554 
sequence was generated using a reverse strand primer. The four nucleotides located 555 
between the dashed red lines are duplicated from the proximal breakpoint.  556 
 557 
Figure 3: A schematic representation of the SCAI locus, displaying the exon 558 
arrangement of the SMAD4 processed pseudogene, which is consistent with that 559 
reported for NM_005359.5 (https://www.ncbi.nlm.nih.gov/nucleotide/). Exons (green 560 
boxes) are drawn to scale using GeneDrawer 561 
(www.insilicase.com/Desktop/GeneDrawer.aspx, last accessed August 18, 2017). 562 
 563 
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Table 1: The ratio of gapped to non-gapped sequence alignments in cases with an apparent SMAD4 intron 6 deletion. 
Sample 
Gapped read alignments 
spanning intron 6 
Mean per-base read depth 
for intron 6 nucleotides 
Ratio of gapped to non-
gapped reads 
1 1,620 3,069 1:1.89 
2 739 1,750 1:2.37 
3 571 1,183 1:2.07 
4 1,198 2,250 1:1.88 
5 770 1,323 1:1.72 
Intron numbering determined according to NM_005359.5 (https://www.ncbi.nlm.nih.gov/nucleotide/). 
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Table 2: Characteristics of whole genome sequencing reads supporting the intragenic SCAI integration site. 
Str.: Strand. CIGAR: The mapping defined by the BWA alignment. All coordinates are provided according to human genome build hg19. 
Locus represents the read mapping to one of three possible loci, either the 5’ end of the SMAD4 pseudogene (5’-SMAD4), the 3’ end of the 
SMAD4 pseudogene (3’-SMAD4), or the SCAI integration site (SCAI). 
 
 
 
 
 
 
 
Sample Read pair ID 
Read 1 Read 2 
Locus Chr. Start Str. CIGAR Locus Chr. Start Str. CIGAR 
2 4:13608:15564:14605 5’-SMAD4 18 48,556,641 - 151M SCAI 9 127,732,358 + 150M 
2 2:13210:1908:2419 SCAI 9 127,732,501 + 151M 5’-SMAD4 18 48,556,701 - 6S143M 
2 4:22402:24489:4305 5’-SMAD4 18 48,556,700 - 151M SCAI 9 127,732,506 + 150M 
2 1:11204:8894:18752 5’-SMAD4 18 48,556,624 - 60S91M SCAI 9 127,732,633 + 81M70S 
2 4:21606:19277:14299 SCAI 9 127,732,700 - 24S127M 3’-SMAD4 18 48,605,924 + 101M49S 
3 3:22511:22720:13254 5’-SMAD4 18 48,556,622 - 151M SCAI 9 127,732,422 + 151M 
3 2:11311:9152:15694 5’-SMAD4 18 48,556,624 - 60S91M SCAI 9 127,732,437 + 151M 
3 2:21212:20833:4797 SCAI 9 127,732,556 + 150M 5’-SMAD4 18 48,556,624 - 64S87M 
3 1:21211:11117:11719 3’-SMAD4 18 48,605,995 + 150M SCAI 9 127,732,700 - 87S62M 
4 3:13407:5904:6688 5’-SMAD4 18 48,556,711 - 151M SCAI 9 127,732,459 + 150M 
4 1:11210:11536:3015 5’-SMAD4 18 48,556,624 - 58S93M SCAI 9 127,732,487 + 151M 
4 2:21206:5607:15745 5’-SMAD4 18 48,556,624 - 48S103M SCAI 9 127,732,604 + 110M41S 
5 4:13501:18475:17089 5’-SMAD4 18 48,556,624 - 45S106M SCAI 9 127,732,552 + 150M 
5 4:11605:22916:12006 SCAI 9 127,732,569 + 145M6S 5’-SMAD4 18 48,556,635 - 151M 
5 4:12410:4727:7249 5’-SMAD4 18 48,556,800 - 151M SCAI 9 127,732,582 + 132M19S 
5 4:23601:11116:11521 SCAI 9 127,732,607 + 107M44S 5’-SMAD4 18 48,556,882 - 2S114M35S 
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